126937-41-5 Usage
General Description
N-4-BOC-N-1-CBZ-2-PIPERAZINE CARBOXYLIC ACID is a complex compound used in the field of chemistry, especially in pharmaceutical research. These compounds belong to the category of organic compounds called piperazines. This particular type of chemical is synthesized for usage primarily in laboratory settings. BOC (tert-butyloxycarbonyl) and CBZ (carboxybenzyl) are both protective groups used in organic synthesis to protect the amine groups in piperazine during reactions. Piperazines are heterocyclic organic compounds that contain a six-membered ring with two opposing nitrogen atoms, often used in the creation of various drugs, including antipsychotics and antibiotics. Carboxylic acids are organic compounds containing a carboxyl group, which enables them to donate protons, making them generally acidic. The applications and properties of this compound will largely depend on the specific context of its use, but it's mainly utilized in the synthesis and development of more complex molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 126937-41-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,9,3 and 7 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 126937-41:
(8*1)+(7*2)+(6*6)+(5*9)+(4*3)+(3*7)+(2*4)+(1*1)=145
145 % 10 = 5
So 126937-41-5 is a valid CAS Registry Number.
126937-41-5Relevant articles and documents
TRICYCLIC PYRIDONES AND PYRIMIDONES
-
Paragraph 0723; 0730-0732, (2021/06/26)
A compound of Formula (I) is provided: (I) where the variables are defined herein.
ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS
-
Page/Page column 58-60, (2020/05/21)
Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO
-
Page/Page column 113, (2018/09/19)
The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
